We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Benchmark Holdings Plc | LSE:BMK | London | Ordinary Share | GB00BGHPT808 | ORD 0.1P |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| 0.00 | 0.00% | 24.70 | 54,509 | 16:35:15 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| 24.60 | 24.80 | 24.60 | 24.60 | 24.60 | |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 147.73M | -39.46M | -0.0533 | -4.62 | 182.86M |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| 15:42:01 | O | 4 | 24.604 | GBX |
| Date | Time | Source | Headline |
|---|---|---|---|
| 14/7/2025 | 15:10 | UK RNS | Castlebar Capital LLP Form 8.3 - BENCHMARK HOLDINGS PLC |
| 10/7/2025 | 15:10 | UK RNS | Castlebar Capital LLP Form 8.3 - BENCHMARK HOLDINGS PLC |
| 10/7/2025 | 07:00 | UK RNS | Gresham House Asset Mgmt Ltd Form 8.3 - Benchmark Holdings PLC |
| 01/7/2025 | 07:00 | UK RNS | Benchmark Holdings PLC Update on Conditions, Tender Offer and Timetable |
| 30/6/2025 | 07:00 | UK RNS | Benchmark Holdings PLC Total Voting Rights |
| 18/6/2025 | 16:30 | UK RNS | Benchmark Holdings PLC Result of GM |
| 12/6/2025 | 15:01 | UK RNS | DNB Asset Management Form 8.3 - BENCHMARK HOLDINGS |
| 12/6/2025 | 09:53 | ALNC |  Benchmark Holdings reports drop in revenue, confirms delisting plans |
| 12/6/2025 | 07:00 | UK RNS | Benchmark Holdings PLC Interim Results |
| 11/6/2025 | 12:20 | UK RNS | DNB Asset Management Form 8.3 - BENCHMARK HOLDINGS PLC |
Benchmark (BMK) Share Charts1 Year Benchmark Chart |
|
1 Month Benchmark Chart |
Intraday Benchmark Chart |
| Date | Time | Title | Posts |
|---|---|---|---|
| 16/6/2025 | 19:10 | Benchmark Holdings Plc | 545 |
| 19/5/2021 | 08:35 | SALMON prices 30 year high and CAT VACCINES are Go-Go | 566 |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|
| Top Posts |
|---|
Posted at 19/7/2025 09:20 by Benchmark Daily Update Benchmark Holdings Plc is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker BMK. The last closing price for Benchmark was 24.70p.Benchmark currently has 740,336,243 shares in issue. The market capitalisation of Benchmark is £182,122,716. Benchmark has a price to earnings ratio (PE ratio) of -4.62. This morning BMK shares opened at 24.60p |
Posted at 16/6/2025 19:10 by edmonda H1 25 results, proposed delisting from LSE AIM, Investor Presentation video recordingResearch note: For the half year to 31 March 2025, Benchmark Holdings reported revenue from continuing operations (post disposal of the Genetics business area) of £40.6m, -22%YoY (-17% CER), primarily resulting from the pause in sea-based sales of Ectosan®Vet and CleanTreat® in the Health business area. The Group recorded an operating loss of £8.4m (H1 24, £7.2m loss), and (adj.) EBITDA of £4.2m, down 56%YoY. On 23 May, the Group announced its intention to cancel its Admission to trading on AIM and Euronext Oslo, subject to approval from shareholders and the Norwegian regulator. As part of the process, CEO Trond Williksen will step down from the Board and CFO Septima Maguire will resign. The planned disposal of the Genetics business was completed on 31 March, realising gross proceeds of £194.0m, from which the Group repaid the outstanding green bond, RCF and hedging instruments to the value of £87m, leaving net cash reserves of £117m. It is proposed to return c.£95m to shareholder via: (i) a c.£56.7m tender offer for up to 226,934,325 Ordinary Shares at 25.0p/share, and (ii) a special dividend, conditional on the outcome of the General Meeting on 18 June. The rationale for de-listing from AIM includes implied annual cost savings totalling an estimated £8.0m (specific AIM-related, £2.4m, and arising from streamlined operations, £5.6m), and reduced management, legal and regulatory responsibilities. In light of the decision to de-list subject to shareholder ratification, we have suspended our Fair Value. Link to note: Video recording - Investor Presentation: Trond Williksen (CEO) and Septima Maguire (CFO) of Benchmark Holdings plc (AIM: BMK, Euronext Growth Oslo: BMK), the aquaculture biotechnology business, hosted an Investor Presentation covering Interim numbers for the six month period ended 31 March. Highlights included the completion of the sale of the Genetics business, resulting in Group profit after tax of £76m, with the continuing business performing in line with expectations. Management discussed the repayment of their Green bond, RCF and related hedging instruments for a total of c. £87m post period end. The team also discussed the recently announced proposals to delist the Company from AIM and Euronext Growth Oslo, and the opportunity for shareholders to roll over into the private company and receive a special dividend. There was a detailed financial overview and a Q&A session where management answered investor queries. The full presentation is available to watch, divided into chapters as below: 0:00:03 Introduction & Agenda 0:00:50 Highlights 0:06:32 Operational Update 0:12:04 Financial Update 0:19:44 Outlook 0:22:20 Q&A Link to video: |
Posted at 12/6/2025 19:30 by mikeh30 It's an easy win for the market makers. Hold the bid 3% under offer price. Punters get bored and sell up and lose that 3%. MMs bank it. |
Posted at 09/6/2025 08:43 by controlledmadness Does anyone think that the vote will not pass? The share price seems to say that it will not as 25p is a guarantee so why would you sell for less. They said they had 70 percent tied up and only need another 5 percent. |
Posted at 01/4/2025 08:48 by jaf111 This is certainly turning out to be a fiasco….far from “unlocking significant shareholder value” the share price has gone from just under 40p to just over 20p!!!!!And the £260m now far exceed the current mkt cap (£170m) And the sold business accounted for only around 1/3rd of turnover…̷ |
Posted at 31/3/2025 16:42 by controlledmadness So if they distribute it all it will be 14.5 pence per share. But I expect it will be about 5p and the rest for the business. |
Posted at 27/3/2025 20:14 by onlymeee Nonsense, stop scaremongering to get a better price.Should be valued closer to 50p when the sale concludes |
Posted at 10/1/2025 14:21 by controlledmadness Put in money terms the equity prediction is about 17p being returned per share in 2025.Is the market saying that the share price has taken this into account or that the resulting company after the 17 p return mat have a 10p a share value? |
Posted at 10/1/2025 10:35 by edmonda "FY24 results: refocus post disposal" - new research (link below)Benchmark Holdings reported FY24 revenue from continuing operations of £90.4m, -13%YoY (currency adjusted, CER, -6%YoY), and (adj.) EBITDA of £11.9m, -30%YoY (CER: -24%YoY reflecting the decline in revenue in the Health business (-57%YoY) and changes in Advanced Nutrition product mix. Net debt was reduced from £65.5m in FY23 to £49.0m due to the impact of the discontinued Genetics business removing debt related to the Saltern facility. The focus is now on the structure of operations post sale of the Genetics business area, streamlining the organisation and reducing costs. Post-divestment our revenue and (adj.) EBITDA outlook is determined principally by two factors: trends in the overall market for shrimp (demand and prices), and contribution from the Health business based on Salmosan®Vet revenue streams, in FY25 respectively £86.7m and £12.7m, and for FY26, £90.9m and £14.0m. We reinstate our fair value at 43p/share, to be reviewed on completion of the disposal process as details of the use of proceeds, structure of the balance sheet and proposals for further restructuring emerge. Our revised Fair Value, based on a 5-year DCF, is inclusive of a return of capital to shareholders which we estimate at £158m, to be paid in FY25 (£128m) and FY27 (£30m). Link to note: |
Posted at 10/1/2025 10:18 by jaf111 Can anyone help explain recent weakness in share price….is there a problem with the Novo sale?Market cap approx £200m which is substantially below the £260m due from Genetics sale. Clearly I must be missing something….. |
Posted at 07/8/2024 13:33 by edmonda Save the Date! 22nd August - Q3 Results Investor Presentation - sign up below!Benchmark Holdings plc (AIM: BMK, Euronext Growth Oslo: BMK), the aquaculture biotechnology business, will be conducting an investor presentation following publication of their Q3 results for the nine month period ended 30 June 2024. The online event will be hosted by Trond Williksen, CEO, and Septima Maguire, CFO, and will take place on Thursday 22nd August at 12.00pm (UK time). The webinar is open to all existing and potential shareholders. Questions can be submitted during the presentation to be addressed at the end. Link to register here: |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
